The prognosis of the patients with medulloblastoma who relapse after initial treatment including radiotherapy remains dismal. A recent study by Peyrl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relapse can improve long-term survival and lead to cure of the patients. In this spotlight piece entitlted : Successfully targeting the cancer system with metronomics for medulloblastoma just published in Trends In Cancer,written wtih Andreas PEYRL, Simon BAILEY and Nicolas ANDRE we discuss in which setting the MEMMAT approach could be used( i.e. upfront, relmapse, maintenance), whihch tumor types beyond medulloblastoma (ie : ATRT, ependymoma) ang propose it works though a global cancer system targetting.

the article is available here